As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.


Figure S1. E.coli Protein and peptide numbers for the 1D and 2D-3 fraction E.coli experiments.

Figure S2. The Venn diagram of the overlap of E.coli proteins and peptides numbers from 1D-LC (A) and 2D-LC (B) analysis between two biological replicates, respectively.

Figure S3. Comparison of subcellular localization from proteins identified by gel-assisted digestion and in-solution digestion, respectively.

Figure S4. Treatment with simvastatin resulted in dose-dependent diminishment of viability of rat primary cultured hepatocytes (A).

Figure S5. The numbers of proteins and peptides identified from 1D-LC and 2D-LC methods (A), the Venn diagram of the overlap of proteins identified from 1-LC and 2D-LC (B).

Figure S6. 2D-5fraction control (A) and simvastatin-treated (B) rat primary hepatocyte separation.

Figure S7. Subcellular localization (A) and functional categorization (B) of differentially expressed genes in simvastatin-induced hepatotoxicity.

Figure S8. Correlation between protein and corresponding transcript modulation. Results presented all common proteins and genes (A) and differentially expressed proteins and genes (B).

Figure S9. A boxplot of the ranking of differentially expressed genes (DEGs) and differentially expressed proteins (DEPs).

Figure S10. mRNA expressions of HMG-COA reductase (HMG-COAR), and low density lipoprotein receptor (LDLR) in simvastatin-treated hepatocytes.

pmic7353-sup-0002-TableS1.xls7133KTable S1. List of proteins identified from twelve runs of control and simvastatin-treated groups.
pmic7353-sup-0003-TableS2.pdf20KTable S2. Gene specific primers used in real-time PCR confirmation experiments.
pmic7353-sup-0004-TableS3.xls69KTable S3. mRNA changes in simvastatin-treated hepatocytes at p < 0.05 and fold change greater than 2.0 or less than 0.5.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.